Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial.
Koch J, Leha A, Bidner H, Cordts I, Dorst J, Günther R, Zeller D, Braun N, Metelmann M, Corcia P, Depla E, Weydt P, Meyer T, Grosskreutz J, Soriani M, Attarian S, Weishaupt J, Weyen U, Kuttler J, Zurek G, Rogers M, Feneberg E, Deschauer M, Neuwirth C, Wuu J, Ludolph A, Schmidt J, Remane Y, Camu W, Friede T, Benatar M, Weber M, Lingor P, ROCK-ALS Study group. Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2024; 23:1133-1146.
01.11.2024
Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial.
01.11.2024
Lancet Neurol 2024; 23:1133-1146
Koch Jan Christoph, Leha Andreas, Bidner Helen, Cordts Isabell, Dorst Johannes, Günther René, Zeller Daniel, Braun Nathalie, Metelmann Moritz, Corcia Philippe, Depla Erik, Weydt Patrick, Meyer Thomas, Grosskreutz Julian, Soriani Marie-Hélène, Attarian Shahram, Weishaupt Jochen H, Weyen Ute, Kuttler Josua, Zurek Gabriela, Rogers Mary-Louise, Feneberg Emily, Deschauer Marcus, Neuwirth Christoph, Wuu Joanne, Ludolph Albert C., Schmidt Jens, Remane Yvonne, Camu William, Friede Tim, Benatar Michael, Weber Markus, Lingor Paul, ROCK-ALS Study group
Weiter
